Voyager Therapeutics Return on Tangible Equity 2014-2022 | VYGR
Current and historical return on tangible equity values for Voyager Therapeutics (VYGR) over the last 10 years. Return on tangible equity can be defined as the amount of net income returned as a percentage of shareholders equity, after subtracting intangible assets, goodwill and preferred equity.
| Voyager Therapeutics Return On Tangible Equity Historical Data |
| Date |
TTM Net Income |
Tangible Equity |
Return on Tangible Equity |
| 2022-03-31 |
$-0.07B |
$0.08B |
-75.88% |
| 2021-12-31 |
$-0.07B |
$0.10B |
-66.20% |
| 2021-09-30 |
$-0.09B |
$0.09B |
-76.23% |
| 2021-06-30 |
$0.02B |
$0.11B |
12.70% |
| 2021-03-31 |
$0.04B |
$0.14B |
29.27% |
| 2020-12-31 |
$0.04B |
$0.15B |
31.03% |
| 2020-09-30 |
$0.04B |
$0.17B |
37.83% |
| 2020-06-30 |
$-0.06B |
$0.08B |
-66.85% |
| 2020-03-31 |
$-0.04B |
$0.08B |
-40.39% |
| 2019-12-31 |
$-0.04B |
$0.10B |
-41.22% |
| 2019-09-30 |
$-0.05B |
$0.11B |
-57.91% |
| 2019-06-30 |
$-0.06B |
$0.12B |
-71.30% |
| 2019-03-31 |
$-0.10B |
$0.10B |
-130.17% |
| 2018-12-31 |
$-0.09B |
$0.05B |
-121.92% |
| 2018-09-30 |
$-0.08B |
$0.07B |
-82.11% |
| 2018-06-30 |
$-0.08B |
$0.08B |
-81.20% |
| 2018-03-31 |
$-0.07B |
$0.10B |
-70.14% |
| 2017-12-31 |
$-0.07B |
$0.13B |
-63.53% |
| 2017-09-30 |
$-0.07B |
$0.09B |
-65.92% |
| 2017-06-30 |
$-0.06B |
$0.11B |
-46.78% |
| 2017-03-31 |
$-0.05B |
$0.12B |
-35.46% |
| 2016-12-31 |
$-0.04B |
$0.14B |
-26.45% |
| 2016-09-30 |
$-0.03B |
$0.15B |
-21.32% |
| 2016-06-30 |
$-0.03B |
$0.16B |
-21.66% |
| 2016-03-31 |
$-0.03B |
$0.16B |
-27.59% |
| 2015-12-31 |
$-0.04B |
$0.17B |
-57.56% |
| 2015-09-30 |
$-0.04B |
$0.10B |
-135.92% |
| 2015-06-30 |
$-0.03B |
|
-12800.00% |
| 2015-03-31 |
$-0.03B |
|
-12000.00% |
| 2014-12-31 |
$-0.02B |
$0.00B |
-6800.00% |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Biomedical and Genetics |
$0.227B |
$0.037B |
|
Voyager Therapeutics, Inc. is a gene therapy company. It focuses on the development of treatments for patients suffering from severe diseases of the central nervous system. Its pipeline includes VY-AADC01, which is in Phase 1b clinical trials for treatment of Parkinson's disease and preclinical programs comprise VY-SOD101 for a monogenic form of amyotrophic lateral sclerosis, VY-FXN01 for Friedreich ataxia and VY-HTT01 for Huntington's disease as well as VY-SMN101 for neuromuscular disease. Voyager Therapeutics, Inc. is headquartered in Cambridge, Massachusetts.
|
